Business Wire

Navitas Life Sciences, a TAKE Solutions Enterprise, has been named as a Leader in IDC MarketScape: Worldwide Life Science R&D BPO Services 2018 Vendor Assessment

Del

Navitas Life Sciences, a wholly owned subsidiary of TAKE Solutions and a full service Clinical, Regulatory & Safety solutions and services provider today announced that it has been recognized as a ‘Leader’ in the IDC MarketScape: Worldwide Life Science R&D BPO Services 2018 Vendor Assessment (Doc # June 2018, IDC #US42144618).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180712005664/en/

Navitas Life Sciences, a TAKE Solutions Enterprise, has been named as a Leader in IDC MarketScape: W ...

Navitas Life Sciences, a TAKE Solutions Enterprise, has been named as a Leader in IDC MarketScape: Worldwide Life Science R&D BPO Services 2018 Vendor Assessment (Photo: Business Wire)

Leadership in this study is based on the breadth of life science R&D business process outsourcing services offered, geographical footprint and global delivery capabilities, industry-specific expertise, and diligent vetting of customer references to examine vendor capabilities. Navitas Life Sciences was one of nine life science R&D IT BPO vendors selected to participate in this study based on the IDC MarketScape’s stringent research and due diligence process.

IDC MarketScape’s vendor assessment:

“Navitas Life Sciences has extensive experience working with pharmaceutical and biotechnology companies of all sizes and across multiple geographies. Navitas Life Sciences is strongly differentiated from its more traditional market competitors by its broad portfolio of clients, ranging from small and midsize organizations to large global pharmaceutical companies. Deep, task-level client experience over a wide variety of specific BPO services also separates Navitas Life Sciences from its peers in this IDC MarketScape. Relative to other vendors discussed in this study and based on feedback from multiple customer references, Navitas Life Sciences received high marks for its technical skills and capabilities, deep bench and proactive approach to project work, and ability to contribute as a strategic partner when needed.”

Ram Yeleswarapu, President, Navitas Life Sciences said, “We are honored that our domain centricity in Life Sciences was recognized in the form of a listing as ‘Leader’ in the prestigious IDC MarketScape 2018 Assessment”. Speaking on the latest technological innovations, he also added, ”Artificial Intelligence (AI) will significantly transform or impact the life sciences space. This along with robotics and cognitive technologies is important for better outcomes, safety, and compliance and lower costs. The use of AI will provide anticipated savings of nearly US$ 150 billion by the mid-2020s for the United States’ healthcare economy.”

Dr. Krishnan Rajagopalan, Chief Growth Officer, Navitas Life Sciences said, “As part of our growth strategy, we are expanding our global operations and services to provide a flexible and scalable partnership model. We leverage our integrated consulting, process and technology capabilities to deliver E2E services and outcomes across quality, compliance, reduced time to market (TAT, Cycle time) and cost. IDC MarketScape’s recognition is timely as we move ahead in this transformative journey with our clients.”

Alan Louie, Research Director of IDC Health Insights' Life Science R&D Strategy and Technology research, noted, "While still somewhat smaller than its traditional IT outsourcing counterpart, BPO in the life sciences remains an important contributor to industry success. The scope of life science R&D BPO continues to expand as more and more processes are operationalized and preferred IT partners are tasked with implementing and maintaining new processes and procedures. As a result, leading IT service providers are increasingly working as partners with their industry sponsors to deliver operational excellence while contributing to ongoing industry transformation that will ultimately automate well-defined, highly repetitive tasks. While IDC continues to expect that IT outsourcing overall will continue to grow by double digits over the next 5–10 years, we also believe that BPO spending has stabilized and should remain relatively constant over the near term."

About Navitas Life Sciences

Navitas Life Sciences delivers platform-driven full-service Clinical, Regulatory and Safety solutions and services. As the dedicated life sciences brand of TAKE Solutions, Navitas Life Sciences operates across North America, Europe, Asia pacific and Latin America. Navitas Life Sciences combines the knowledge and experience of three legacy brands - Ecron Acunova, Navitas, and Intelent. Thus, Navitas brings together the capabilities of a full-service CRO, a technology-led life sciences services provider, and expertise in analytics and data sciences to address critical challenges and drive outcomes for life sciences. Navitas has over 30 years of rich experience across 330+ phase I-IV clinical trials, 20+ therapeutic areas, and 40+ successful GCP/non-GCP audits. Our trial expertise is augmented by OneClinical, a platform that delivers trial oversight, analytics, and insights to drive successful study outcomes.

To learn more, visit www.navitaslifesciences.com.

About IDC MarketScape

IDC MarketScape vendor analysis model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360 degree assessment of the strengths and weaknesses of current and prospective vendors.

Contact information

Navitas Life Sciences
Kate Derham
kate.derham@navitaslifesciences.com
T: +44 (0) 2392 245219

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Samsung Bioepis Announces Results of Additional One-Year Follow-Up Study Comparing Event-Free Survival of SB3 Trastuzumab Biosimilar Candidate to Reference Trastuzumab by ADCC Activity8.12.2018 14:10Pressemelding

Samsung Bioepis Co., Ltd. today announced the results of an additional one-year follow-up study comparing event-free survival (EFS) of SB3, a biosimilar candidate referencing HERCEPTIN® 1 (trastuzumab), to reference trastuzumab (TRZ) by antibody-dependent cell-mediated cytotoxicity (ADCC) activity. ADCC is a key mechanism of action for trastuzumab. The study results are being presented at the 2018 San Antonio Breast Cancer Symposium® (SABCS) which is being held December 4-8, 2018 in San Antonio, Texas. For the study, patients with HER2 positive early or locally advanced breast cancer were randomly assigned to receive SB3 or TRZ concurrently with chemotherapy. Patients then underwent surgery followed by treatment with SB3 or TRZ. Following completion of such therapy, 367 patients participated in a long-term follow-up study, 186 of whom were treated with SB3 and 181 of whom were treated with TRZ. Within the group of 181 patients who received TRZ, 126 patients who were exposed to at least

Harvest Health & Recreation, Inc. to hold Conference Call to Discuss Q3 2018 Results and Performance Outlook7.12.2018 19:00Pressemelding

Harvest Health & Recreation, Inc. (HARV: CSE) will hold its Third Quarter 2018 earnings conference call on: Tuesday, December 11, 2018 8:30 AM (Eastern Time) Participating on the call to review Harvest Health & Recreation’s Third Quarter 2018 financial and operating results will be Jason Vedadi, Executive Chairman, Steve White, Chief Executive Officer, and Steve Gutterman, President. Third quarter results are available at www.harvestinc.com/news. To participate in the conference call, please dial: US toll free +1-866-777-2509 Canada toll free +1-866-605-3852 UK toll free +44-080-823-89064 International dial in +1-412-317-5413 Registration is required; please dial in at least ten minutes prior to the scheduled start time. Webcast: https://services.choruscall.com/links/harv181211.html The conference call will be available for replay for 3 months at: https://services.choruscall.com/links/harv181211.html. About Harvest Health & Recreation, Inc. Harvest Health & Recreation, Inc. is one of t

David Hall Wows Industry with New Technology Solution for Space Exploration7.12.2018 14:01Pressemelding

David Hall is one of history’s rare technological visionaries with the imagination and technical wherewithal to recognize a problem, conceive a solution, and then build something that works. On December 6 at the U.S. Chamber of Commerce’s event, LAUNCH: Industry Taking Off, David Hall presented his world-changing solution to a longstanding problem: how to carry materials and people into space safely, reliably, and efficiently. The audience of industry, military, and policy representatives heard from Hall as well as keynote remarks from Secretary of the Air Force, Heather Wilson; NASA Administrator, Jim Bridenstine; Under Secretary of Defense for Research and Engineering, Michael Griffin; NOAA Deputy Administrator, Dr. Neil Jacobs; and Commerce Secretary, Wilbur Ross. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181207005226/en/ Velodyne Lidar, Inc. Founder and CEO David Hall (Photo: Business Wire) Hall’s proposal involves

Raj Subramaniam Named as FedEx Express President and CEO7.12.2018 14:00Pressemelding

FedEx Corp. (NYSE:FDX) announced today that David L. Cunningham, president and chief executive officer of FedEx Express, will retire effective December 31, 2018. Raj Subramaniam, currently executive vice president, chief marketing and communications officer of FedEx Corporation, will succeed Cunningham effective January 1, 2019. Cunningham began his FedEx career in 1982 in operations at the FedEx Express World Hub in Memphis, Tenn. Over his more than 36-year career, David held numerous leadership positions across the FedEx Express operating company in multiple regions, including chief operating officer and president - international, FedEx Express Asia Pacific chief financial officer, and regional president of the Asia Pacific region. Most recently as president and CEO of FedEx Express, David has been responsible for the leadership and direction of the FedEx Express group, which includes FedEx Express and TNT. Subramaniam has been with FedEx for more than 27 years and has held various e

CORRECTING and REPLACING The Dedica Anthology Completes Its Planned Refinancing7.12.2018 11:43Pressemelding

The first sentence of the release should read: Milan-based hotel group The Dedica Anthology is pleased to announce that it successfully completed its planned €337 million refinancing. (instead of Milan-based hotel group The Dedica Anthology is pleased to announce that today it successfully completed its planned €337 million refinancing). The corrected release reads: THE DEDICA ANTHOLOGY COMPLETES ITS PLANNED REFINANCING Milan-based hotel group The Dedica Anthology is pleased to announce that it successfully completed its planned €337 million refinancing. The lender is Blackstone Real Estate Debt Strategies, and the facilities will refinance legacy loans and provide additional capital for The Dedica Anthology – owned by global alternative investment firm Värde Partners – to invest significantly in its estate. London-based real estate specialist JLL advised Värde Partners on the transaction. Stephen Alden, CEO of The Dedica Anthology, commented: “We are delighted to have completed this c

The Dedica Anthology Completes Its Planned Refinancing7.12.2018 10:48Pressemelding

Milan-based hotel group The Dedica Anthology is pleased to announce that today it successfully completed its planned €337 million refinancing. The lender is Blackstone Real Estate Debt Strategies, and the facilities will refinance legacy loans and provide additional capital for The Dedica Anthology – owned by global alternative investment firm Värde Partners – to invest significantly in its estate. London-based real estate specialist JLL advised Värde Partners on the transaction. Stephen Alden, CEO of The Dedica Anthology, commented: “We are delighted to have completed this complex refinancing. Our own team, the board, our advisors and the lending group have worked hard in collaboration to achieve this excellent result. Our focus is now fully on building The Dedica Anthology brand, carrying out strategic renovation and restoration work on our distinctive properties, strengthening our team and growing our business.” Alessandro Grassivaro, CFO of The Dedica Anthology, added, “Dedica now